Literature DB >> 156196

Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency.

N Aoki, H Saito, T Kamiya, K Koie, Y Sakata, M Kobakura.   

Abstract

alpha(2)-Plasmin inhibitor (alpha(2)PI) is a recently characterized, fast-reacting plasmin inhibitor in human plasma that appears to play an important role in regulation of in vivo fibrinolysis. We report here a case of complete deficiency of alpha(2)PI in man. The patient, a 25-yr-old Japanese man, had a life-long severe bleeding tendency (hemarthrosis and excessive bleeding after trauma). The following tests were within normal limits: platelet count, bleeding time, thrombin time, prothrombin time, partial thromboplastin time, titers of known clotting factors, platelet glass bead retention, Factor VIII-related antigen, platelet aggregation by ADP, collagen and ristocetin, and clot retraction. Routine liver function tests were also normal. The only abnormal finding was that whole blood clot lysis was extemely rapid and was complete in 4-8 h. The concentration of plasma protease inhibitors, including alpha(2)-macro-globulin, antithrombin III, alpha(1)-antitrypsin, and C1INH, were all normal. The concentration of alpha(2)-PI in the patient's plasma, assayed by immunological methods, was <0.1 mg/100 ml (normal concentration, 6.1+/-0.88 mg/100 ml [mean+/-SE]) and functional assays showed a complete deficiency of alpha(2)PI. Addition of purified alpha(2)PI to the patient's whole blood completely corrected the accelerated fibrinolysis. The patient's parents, four siblings, and four other members of this family were asymptomatic, but the titers of alpha(2)PI in their plasmas were congruent with50% of normal pooled plasma. There were three consanguineous marriages in this family, and the alpha(2)PI deficiency appears to have been inherited as an autosomal recessive trait. We speculate that alpha(2)PI deficiency in this patient has led to uninhibited in vivo fibrinolysis that probably causes the severe hemorrhagic tendency. Thus, this study indicates the important role of alpha(2)PI in hemostasis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 156196      PMCID: PMC372028          DOI: 10.1172/jci109387

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Properties of a partially purified preparation of a circulating plasminogen activator.

Authors:  D Ogston; B Bennett; M Mackie
Journal:  Thromb Res       Date:  1976-03       Impact factor: 3.944

2.  Inhibition of plasminogen binding to fibrin by alpha2-plasmin inhibitor.

Authors:  M Moroi; N Aoki
Journal:  Thromb Res       Date:  1977-06       Impact factor: 3.944

3.  The resistance of fibrinogen and soluble fibrin monomer in blood to degradation by a potent plasminogen activator derived from cadaver limbs.

Authors:  V Gurewich; E Hyde; B Lipinski
Journal:  Blood       Date:  1975-10       Impact factor: 22.113

4.  Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids.

Authors:  S Thorsen
Journal:  Biochim Biophys Acta       Date:  1975-05-30

5.  The behavior of alpha2-plasmin inhibitor in fibrinolytic states.

Authors:  N Aoki; M Moroi; M Matsuda; K Tachiya
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

6.  The alpha2-plasmin inhibitor levels in liver diseases.

Authors:  N Aoki; T Yamanaka
Journal:  Clin Chim Acta       Date:  1978-03-01       Impact factor: 3.786

7.  Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate.

Authors:  A C Teger-Nilsson; P Friberger; E Gyzander
Journal:  Scand J Clin Lab Invest       Date:  1977-09       Impact factor: 1.713

8.  Effects of alpha2-plasmin inhibitor on fibrin clot lysis. Its comparison with alpha2-macroglobulin.

Authors:  N Aoki; M Moroi; K Tachiya
Journal:  Thromb Haemost       Date:  1978-02-28       Impact factor: 5.249

9.  Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis.

Authors:  M Moroi; N Aoki
Journal:  J Biol Chem       Date:  1976-10-10       Impact factor: 5.157

10.  Plasmin inhibitor interactions. The effectiveness of alpha2-plasmin inhibitor in the presence of alpha2-macroglobulin.

Authors:  P C Harpel
Journal:  J Exp Med       Date:  1977-10-01       Impact factor: 14.307

View more
  24 in total

1.  Variability in international normalized ratio and activated partial thromboplastin time after injury are not explained by coagulation factor deficits.

Authors:  Gregory R Stettler; Ernest E Moore; Hunter B Moore; Geoffrey R Nunns; Julia R Coleman; Arthur Colvis; Arsen Ghasabyan; Mitchell J Cohen; Christopher C Silliman; Anirban Banerjee; Angela Sauaia
Journal:  J Trauma Acute Care Surg       Date:  2019-09       Impact factor: 3.313

2.  The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival.

Authors:  K M Dougherty; J M Pearson; A Y Yang; R J Westrick; M S Baker; D Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

3.  alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.

Authors:  C Kluft; H K Nieuwenhuis; D C Rijken; E Groeneveld; G Wijngaards; W van Berkel; G Dooijewaard; J J Sixma
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

4.  Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay.

Authors:  P C Harpel
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

5.  Noncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites.

Authors:  Galina Tsurupa; Sergiy Yakovlev; Patrick McKee; Leonid Medved
Journal:  Biochemistry       Date:  2010-09-07       Impact factor: 3.162

6.  Synergistic fibrinolysis: combined effects of plasminogen activators and an antibody that inhibits alpha 2-antiplasmin.

Authors:  G L Reed; G R Matsueda; E Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

7.  Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation.

Authors:  M W Mosesson; K R Siebenlist; I Hernandez; K N Lee; V J Christiansen; P A McKee
Journal:  J Thromb Haemost       Date:  2008-06-16       Impact factor: 5.824

8.  Synthesis and secretion of alpha 2-plasmin inhibitor by established human liver cell lines.

Authors:  H Saito; L T Goodnough; B B Knowles; D P Aden
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

9.  Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.

Authors:  Y Sakata; N Aoki
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

10.  Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.

Authors:  J Mimuro; S Kimura; N Aoki
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.